202 related articles for article (PubMed ID: 8640976)
41. Effect of antiplatelet agents clopidogrel, aspirin, and cilostazol on circulating tissue factor procoagulant activity in patients with peripheral arterial disease.
Rao AK; Vaidyula VR; Bagga S; Jalagadugula G; Gaughan J; Wilhite DB; Comerota AJ
Thromb Haemost; 2006 Dec; 96(6):738-43. PubMed ID: 17139367
[TBL] [Abstract][Full Text] [Related]
42. Complete inhibition of endotoxin-induced coagulation activation in chimpanzees with a monoclonal Fab fragment against factor VII/VIIa.
Biemond BJ; Levi M; ten Cate H; Soule HR; Morris LD; Foster DL; Bogowitz CA; van der Poll T; Büller HR; ten Cate JW
Thromb Haemost; 1995 Feb; 73(2):223-30. PubMed ID: 7792734
[TBL] [Abstract][Full Text] [Related]
43. Ligand-induced protease receptor translocation into caveolae: a mechanism for regulating cell surface proteolysis of the tissue factor-dependent coagulation pathway.
Sevinsky JR; Rao LV; Ruf W
J Cell Biol; 1996 Apr; 133(2):293-304. PubMed ID: 8609163
[TBL] [Abstract][Full Text] [Related]
44. Antithrombin deficiency increases thrombin activity after prolonged cardiopulmonary bypass.
Sniecinski R; Szlam F; Chen EP; Bader SO; Levy JH; Tanaka KA
Anesth Analg; 2008 Mar; 106(3):713-8, table of contents. PubMed ID: 18292407
[TBL] [Abstract][Full Text] [Related]
45. [Biology and physiopathology of tissue factor and its relevance for cardiovascular diseases].
Del Turco S; De Caterina R
Ital Heart J Suppl; 2003 Jul; 4(7):559-68. PubMed ID: 14558284
[TBL] [Abstract][Full Text] [Related]
46. Protamine inhibits tissue factor-initiated extrinsic coagulation.
Chu AJ; Wang ZG; Raicu M; Beydoun S; Ramos N
Br J Haematol; 2001 Nov; 115(2):392-9. PubMed ID: 11703341
[TBL] [Abstract][Full Text] [Related]
47. Activated coagulation factors in human malignant effusions and their contribution to cancer cell metastasis and therapy.
Gieseler F; Lühr I; Kunze T; Mundhenke C; Maass N; Erhart T; Denker M; Beckmann D; Tiemann M; Schulte C; Dohrmann P; Cavaillé F; Godeau F; Gespach C
Thromb Haemost; 2007 Jun; 97(6):1023-30. PubMed ID: 17549306
[TBL] [Abstract][Full Text] [Related]
48. Thrombogenic mechanisms in the human: fresh insights obtained by immunodiagnostic studies of coagulation markers.
Boisclair MD; Philippou H; Lane DA
Blood Coagul Fibrinolysis; 1993 Dec; 4(6):1007-21. PubMed ID: 8148474
[TBL] [Abstract][Full Text] [Related]
49. Activation of the tissue factor pathway of blood coagulation in patients with chronic urticaria.
Asero R; Tedeschi A; Coppola R; Griffini S; Paparella P; Riboldi P; Marzano AV; Fanoni D; Cugno M
J Allergy Clin Immunol; 2007 Mar; 119(3):705-10. PubMed ID: 17204316
[TBL] [Abstract][Full Text] [Related]
50. Challenges with heparin-based anticoagulation during cardiopulmonary bypass in children: Impact of low antithrombin activity.
Manlhiot C; Gruenwald CE; Holtby HM; Brandão LR; Chan AK; Van Arsdell GS; McCrindle BW
J Thorac Cardiovasc Surg; 2016 Feb; 151(2):444-50. PubMed ID: 26553458
[TBL] [Abstract][Full Text] [Related]
51. Monitoring high-dose heparinization during cardiopulmonary by-pass--a comparison between prothrombinase-induced clotting time (PiCT) and two chromogenic anti-factor Xa activity assays.
Raivio P; Kuitunen A; Petäjä J; Ilveskero S; Lassila R
Thromb Haemost; 2008 Feb; 99(2):427-34. PubMed ID: 18278195
[TBL] [Abstract][Full Text] [Related]
52. [Activation of the blood coagulation system during gram-negative infections and endotoxemias].
Lüscher EF
Fortschr Med; 1975 Aug; 93(22-23):1072-6. PubMed ID: 1225791
[TBL] [Abstract][Full Text] [Related]
53. The impact of cardiac ischemia and reperfusion on markers of activated haemostasis and fibrinolysis during cardiopulmonary bypass: comparison of plasma levels in arterial and coronary venous blood.
Kalweit G; Bach J; Huwer H; Winning J; Hellstern P
Thromb Res; 2005; 116(1):33-9. PubMed ID: 15850606
[TBL] [Abstract][Full Text] [Related]
54. Tissue factor as the main activator of the coagulation system during cardiopulmonary bypass.
De Somer F; Van Belleghem Y; Caes F; François K; Van Overbeke H; Arnout J; Taeymans Y; Van Nooten G
J Thorac Cardiovasc Surg; 2002 May; 123(5):951-8. PubMed ID: 12019381
[TBL] [Abstract][Full Text] [Related]
55. Pro- and non-coagulant forms of non-cell-bound tissue factor in vivo.
Sturk-Maquelin KN; Nieuwland R; Romijn FP; Eijsman L; Hack CE; Sturk A
J Thromb Haemost; 2003 Sep; 1(9):1920-6. PubMed ID: 12941032
[TBL] [Abstract][Full Text] [Related]
56. Human cell-derived microparticles promote thrombus formation in vivo in a tissue factor-dependent manner.
Biró E; Sturk-Maquelin KN; Vogel GM; Meuleman DG; Smit MJ; Hack CE; Sturk A; Nieuwland R
J Thromb Haemost; 2003 Dec; 1(12):2561-8. PubMed ID: 14738565
[TBL] [Abstract][Full Text] [Related]
57. Infant cardiopulmonary bypass: a procoagulant state.
Jaggers JJ; Neal MC; Smith PK; Ungerleider RM; Lawson JH
Ann Thorac Surg; 1999 Aug; 68(2):513-20. PubMed ID: 10475421
[TBL] [Abstract][Full Text] [Related]
58. Hemodilution on Cardiopulmonary Bypass: Thromboelastography Patterns and Coagulation-Related Outcomes.
Ranucci M; Baryshnikova E; Ciotti E; Ranucci M; Silvetti S;
J Cardiothorac Vasc Anesth; 2017 Oct; 31(5):1588-1594. PubMed ID: 28778772
[TBL] [Abstract][Full Text] [Related]
59. Changes in blood coagulation during and following cardiopulmonary bypass: lack of correlation with clinical bleeding.
Gelb AB; Roth RI; Levin J; London MJ; Noall RA; Hauck WW; Cloutier M; Verrier E; Mangano DT
Am J Clin Pathol; 1996 Jul; 106(1):87-99. PubMed ID: 8701939
[TBL] [Abstract][Full Text] [Related]
60. Selective tissue factor/factor VIIa Inhibitor, ER-410660, and its prodrug, E5539, have anti-venous and anti-arterial thrombotic effects with a low risk of bleeding.
Nagakura T; Tabata K; Kira K; Hirota S; Clark R; Matsuura F; Hiyoshi H
Thromb Res; 2013 Aug; 132(2):271-9. PubMed ID: 23827699
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
